We learned indeed that the single inhibition of IL-1α/β was of limited efficacy in treating RA patients, despite extremely promising preclinical data [83]; likely, this discrepancy relates to the redundancy of other proinflammatory compensatory pathways such as TNFα, IL-6, or other IL-1 family members like IL-36. Here, IL1A is linked to rheumatoid arthritis.